Abnormal tau lesions (non-argyrophilic pretangle material, argyrophilic neuropil threads,
neurofibrillary tangles) in select types of neurons are crucial for the pathogenesis of sporadic …

Despite tremendous investments in understanding the complex molecular mechanisms
underlying Alzheimer disease (AD), recent clinical trials have failed to show efficacy. A …

Alzheimer's disease (AD) is the leading cause of dementia, accounting for 60–70% of all
cases [Hebert et al., 2003, 1]. The need for effective therapies for AD is great. Current …

The amyloid cascade model of Alzheimer's disease posits the primacy of amyloid beta
deposition preceding tau-mediated neurofibrillary tangle formation. The amyloid-tau …

Use of selective in-vivo tau imaging will enable improved understanding of tau aggregation
in the brain, facilitating research into causes, diagnosis, and treatment of major tauopathies …

Importance In vivo tau imaging may become a diagnostic marker for Alzheimer disease (AD)
and provides insights into the pathophysiology of AD. Objective To evaluate the usefulness …

Tau protein aggregates in several neurodegenerative disorders, referred to as tauopathies.
The tau isoforms observed in post mortem human brain aggregates is used to classify …

Tau and amyloid beta (Aβ) are the prime suspects for driving pathology in Alzheimer's
disease (AD) and, as such, have become the focus of therapeutic development. Recent …

Amyloid imaging is currently introduced to the market for clinical use. We will review the
evidence demonstrating that the different amyloid PET ligands that are currently available …

Background Alzheimer's disease (AD) is the most common neurodegenerative disorder.
Depositions of amyloid β peptide (Aβ) and tau protein are among the major pathological …